Pharma Deal Made Monopoly For Diabetes Drug, Buyer Says
A proposed class action in California federal court claims that the drugmakers behind the brand-name and generic versions of the diabetes drug Glumetza conspired to protect a monopoly that left patients...To view the full article, register now.
Already a subscriber? Click here to view full article